JP7510358B2 - Ｔｒｋ受容体の調節剤としての４－置換フェニル－１，３，５－トリアジン誘導体 - Google Patents

Info

Publication number

JP7510358B2

JP7510358B2 JP2020570716A JP2020570716A JP7510358B2 JP 7510358 B2 JP7510358 B2 JP 7510358B2 JP 2020570716 A JP2020570716 A JP 2020570716A JP 2020570716 A JP2020570716 A JP 2020570716A JP 7510358 B2 JP7510358 B2 JP 7510358B2

Authority

JP

Japan

Prior art keywords

disease

methyl

groups

compound

optionally substituted

Prior art date

2018-06-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• -1 4-Substituted phenyl-1,3,5-triazine Chemical class 0.000 title claims description 122
• 150000001875 compounds Chemical class 0.000 claims description 353
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 109
• 125000000217 alkyl group Chemical group 0.000 claims description 107
• 125000001153 fluoro group Chemical group F* 0.000 claims description 100
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 76
• 108010025020 Nerve Growth Factor Proteins 0.000 claims description 67
• 201000010099 disease Diseases 0.000 claims description 65
• 238000011282 treatment Methods 0.000 claims description 64
• 208000024827 Alzheimer disease Diseases 0.000 claims description 61
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 56
• 150000003839 salts Chemical class 0.000 claims description 56
• 230000011664 signaling Effects 0.000 claims description 55
• 102000007072 Nerve Growth Factors Human genes 0.000 claims description 52
• 125000003545 alkoxy group Chemical group 0.000 claims description 52
• 208000018737 Parkinson disease Diseases 0.000 claims description 48
• 206010012289 Dementia Diseases 0.000 claims description 46
• 238000000034 method Methods 0.000 claims description 46
• 208000035475 disorder Diseases 0.000 claims description 44
• 230000001228 trophic effect Effects 0.000 claims description 42
• 230000001771 impaired effect Effects 0.000 claims description 41
• 208000010877 cognitive disease Diseases 0.000 claims description 40
• 206010010774 Constipation Diseases 0.000 claims description 36
• 239000003814 drug Substances 0.000 claims description 33
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 28
• 208000008589 Obesity Diseases 0.000 claims description 26
• 235000020824 obesity Nutrition 0.000 claims description 26
• 239000008194 pharmaceutical composition Substances 0.000 claims description 26
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 26
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 25
• 208000006289 Rett Syndrome Diseases 0.000 claims description 25
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 25
• 230000002265 prevention Effects 0.000 claims description 25
• 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 24
• 208000028698 Cognitive impairment Diseases 0.000 claims description 23
• 208000026072 Motor neurone disease Diseases 0.000 claims description 23
• 206010012601 diabetes mellitus Diseases 0.000 claims description 22
• 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 22
• 229940124597 therapeutic agent Drugs 0.000 claims description 22
• 125000002947 alkylene group Chemical group 0.000 claims description 21
• 201000000980 schizophrenia Diseases 0.000 claims description 21
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 20
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 20
• 208000005264 motor neuron disease Diseases 0.000 claims description 19
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 19
• 125000001246 bromo group Chemical group Br* 0.000 claims description 18
• 125000002883 imidazolyl group Chemical group 0.000 claims description 18
• 125000001425 triazolyl group Chemical group 0.000 claims description 18
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 17
• 229910052736 halogen Inorganic materials 0.000 claims description 17
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 16
• 201000002832 Lewy body dementia Diseases 0.000 claims description 16
• 150000002367 halogens Chemical class 0.000 claims description 16
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 16
• 208000022873 Ocular disease Diseases 0.000 claims description 15
• 208000001132 Osteoporosis Diseases 0.000 claims description 15
• 230000009286 beneficial effect Effects 0.000 claims description 15
• VMVZGGPZNHFGKS-UHFFFAOYSA-N ethyl n-(oxomethylidene)carbamate Chemical compound CCOC(=O)N=C=O VMVZGGPZNHFGKS-UHFFFAOYSA-N 0.000 claims description 15
• 208000016354 hearing loss disease Diseases 0.000 claims description 13
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 13
• 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 claims description 13
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 13
• 201000004569 Blindness Diseases 0.000 claims description 12
• 206010011878 Deafness Diseases 0.000 claims description 12
• 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 12
• 201000006417 multiple sclerosis Diseases 0.000 claims description 12
• 208000019901 Anxiety disease Diseases 0.000 claims description 11
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 11
• 208000023105 Huntington disease Diseases 0.000 claims description 11
• 206010021143 Hypoxia Diseases 0.000 claims description 11
• 208000006011 Stroke Diseases 0.000 claims description 11
• 208000034799 Tauopathies Diseases 0.000 claims description 11
• 206010043248 Tendon rupture Diseases 0.000 claims description 11
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 11
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
• 208000029028 brain injury Diseases 0.000 claims description 11
• 208000018631 connective tissue disease Diseases 0.000 claims description 11
• 125000005843 halogen group Chemical group 0.000 claims description 11
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 11
• 238000002360 preparation method Methods 0.000 claims description 11
• 230000008569 process Effects 0.000 claims description 11
• 208000020431 spinal cord injury Diseases 0.000 claims description 11
• 230000009529 traumatic brain injury Effects 0.000 claims description 11
• 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
• 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 9
• 206010036631 Presenile dementia Diseases 0.000 claims description 9
• 239000002671 adjuvant Substances 0.000 claims description 9
• 230000036506 anxiety Effects 0.000 claims description 9
• 230000000112 colonic effect Effects 0.000 claims description 9
• 239000003085 diluting agent Substances 0.000 claims description 9
• 210000005036 nerve Anatomy 0.000 claims description 9
• 208000016192 Demyelinating disease Diseases 0.000 claims description 8
• 208000002193 Pain Diseases 0.000 claims description 8
• 208000010886 Peripheral nerve injury Diseases 0.000 claims description 8
• 206010039966 Senile dementia Diseases 0.000 claims description 8
• 239000002253 acid Substances 0.000 claims description 8
• 230000003412 degenerative effect Effects 0.000 claims description 8
• 206010015037 epilepsy Diseases 0.000 claims description 8
• 230000010370 hearing loss Effects 0.000 claims description 8
• 231100000888 hearing loss Toxicity 0.000 claims description 8
• 230000007954 hypoxia Effects 0.000 claims description 8
• 208000028867 ischemia Diseases 0.000 claims description 8
• 230000009689 neuronal regeneration Effects 0.000 claims description 8
• 230000019491 signal transduction Effects 0.000 claims description 8
• 230000000472 traumatic effect Effects 0.000 claims description 8
• 230000002792 vascular Effects 0.000 claims description 8
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 7
• 230000002035 prolonged effect Effects 0.000 claims description 7
• 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims description 6
• 208000030053 Opioid-Induced Constipation Diseases 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 6
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
• 238000002054 transplantation Methods 0.000 claims description 6
• 208000009829 Lewy Body Disease Diseases 0.000 claims description 4
• 230000001054 cortical effect Effects 0.000 claims description 4
• 239000013066 combination product Substances 0.000 claims description 3
• 229940127555 combination product Drugs 0.000 claims description 3
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
• JJDNQLAPHDJWFS-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[3-(2-oxo-2-pyrazol-1-ylethoxy)-4-phenoxyphenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC=1C=C(C=CC=1)N1C(N(C(NC1=O)=O)C1=CC(=C(C=C1)OC1=CC=CC=C1)OCC(N1N=CC=C1)=O)=O JJDNQLAPHDJWFS-UHFFFAOYSA-N 0.000 claims description 2
• USPQGSLCSUSZFA-UHFFFAOYSA-N 1-(3-methylphenyl)-3-[4-phenoxy-3-(pyrazol-1-ylmethyl)phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound C=1N(N=CC=1)CC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 USPQGSLCSUSZFA-UHFFFAOYSA-N 0.000 claims description 2
• CUAHCQLIBGVRBA-UHFFFAOYSA-N 1-[3-(1H-imidazol-2-ylmethoxy)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1NC(=NC=1)COC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 CUAHCQLIBGVRBA-UHFFFAOYSA-N 0.000 claims description 2
• NRFAHLSXMNUHPC-UHFFFAOYSA-N 1-[3-(1H-imidazol-5-ylmethoxy)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1NC(=CN=1)COC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 NRFAHLSXMNUHPC-UHFFFAOYSA-N 0.000 claims description 2
• XQFMXUKPUWDHOG-UHFFFAOYSA-N 1-[3-(4-methylimidazol-1-yl)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound N=1C(=CN(C=1)C1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1)C XQFMXUKPUWDHOG-UHFFFAOYSA-N 0.000 claims description 2
• MATQYORSAHORSS-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1N(C=CN=1)CC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=CC(C)=C2)=C1 MATQYORSAHORSS-UHFFFAOYSA-N 0.000 claims description 2
• CQJJXUXNSYKFHP-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-(4-methoxyphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=1N(C=CN=1)CC1=C(OC2=CC=CC=C2)C=CC(N2C(=O)NC(=O)N(C2=O)C2=CC=C(OC)C=C2)=C1 CQJJXUXNSYKFHP-UHFFFAOYSA-N 0.000 claims description 2
• HRSNJQDFWWOWDZ-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound N1(C=NC=C1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O HRSNJQDFWWOWDZ-UHFFFAOYSA-N 0.000 claims description 2
• MHRFHKLSJHQLEJ-UHFFFAOYSA-N 1-[3-[(1-ethylpyrazol-4-yl)methyl]-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)N1N=CC(=C1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O MHRFHKLSJHQLEJ-UHFFFAOYSA-N 0.000 claims description 2
• UXUIPEUVVIPUAZ-UHFFFAOYSA-N 1-[3-[(4-ethylpyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)C=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O UXUIPEUVVIPUAZ-UHFFFAOYSA-N 0.000 claims description 2
• WNJCHHFPZKIZCA-UHFFFAOYSA-N 1-[3-[(4-ethylpyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)C=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O WNJCHHFPZKIZCA-UHFFFAOYSA-N 0.000 claims description 2
• NFTSSKBOHVTYGA-UHFFFAOYSA-N 1-[3-[(4-fluoroimidazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC=1N=CN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O NFTSSKBOHVTYGA-UHFFFAOYSA-N 0.000 claims description 2
• HBCCFDWBAPVQDO-UHFFFAOYSA-N 1-[3-[(4-fluoropyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O HBCCFDWBAPVQDO-UHFFFAOYSA-N 0.000 claims description 2
• MCGWGLDGKHMQGB-UHFFFAOYSA-N 1-[3-[(4-fluoropyrazol-1-yl)methyl]-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound FC=1C=NN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O MCGWGLDGKHMQGB-UHFFFAOYSA-N 0.000 claims description 2
• AXXSGYLDABJVJT-UHFFFAOYSA-N 1-[3-[(4-methylimidazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound CC=1N=CN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O AXXSGYLDABJVJT-UHFFFAOYSA-N 0.000 claims description 2
• CIGXRYZOSNICGE-UHFFFAOYSA-N 1-[3-[(5-methylimidazol-1-yl)methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CN=CN1CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O CIGXRYZOSNICGE-UHFFFAOYSA-N 0.000 claims description 2
• IYFFSVLCAWSOHY-UHFFFAOYSA-N 1-[3-[[4-(difluoromethyl)imidazol-1-yl]methyl]-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC(C=1N=CN(C=1)CC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O)F IYFFSVLCAWSOHY-UHFFFAOYSA-N 0.000 claims description 2
• OSCXEQPBXJAEPZ-UHFFFAOYSA-N 1-[4-(4-ethylphenoxy)-3-(pyrazol-1-ylmethyl)phenyl]-3-methyl-1,3,5-triazinane-2,4,6-trione Chemical compound C(C)C1=CC=C(OC2=C(C=C(C=C2)N2C(N(C(NC2=O)=O)C)=O)CN2N=CC=C2)C=C1 OSCXEQPBXJAEPZ-UHFFFAOYSA-N 0.000 claims description 2
• GJAZUILPMWGGPP-UHFFFAOYSA-N 1-[4-(4-fluorophenoxy)-3-(imidazol-1-ylmethyl)phenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound FC1=CC=C(OC2=C(C=C(C=C2)N2C(N(C(NC2=O)=O)C2=CC(=CC=C2)C)=O)CN2C=NC=C2)C=C1 GJAZUILPMWGGPP-UHFFFAOYSA-N 0.000 claims description 2
• JHKMYLLMMBBDKE-UHFFFAOYSA-N 1-[4-phenoxy-3-(1,2,4-triazol-1-ylmethyl)phenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound O(C1=CC=CC=C1)C1=C(C=C(C=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O)CN1N=CN=C1 JHKMYLLMMBBDKE-UHFFFAOYSA-N 0.000 claims description 2
• XDEFQYLLZMGLKN-UHFFFAOYSA-N 1-[4-phenoxy-3-(pyrazol-1-ylmethyl)phenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound O(C1=CC=CC=C1)C1=C(C=C(C=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O)CN1N=CC=C1 XDEFQYLLZMGLKN-UHFFFAOYSA-N 0.000 claims description 2
• KGUXEQIFZMEAHW-UHFFFAOYSA-N 1-methyl-3-[4-phenyl-3-(pyrazol-1-ylmethyl)phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CN1C(N(C(NC1=O)=O)C1=CC(=C(C=C1)C1=CC=CC=C1)CN1N=CC=C1)=O KGUXEQIFZMEAHW-UHFFFAOYSA-N 0.000 claims description 2
• 210000004227 basal ganglia Anatomy 0.000 claims 2
• 230000002490 cerebral effect Effects 0.000 claims 2
• 230000007850 degeneration Effects 0.000 claims 2
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 176
• 239000011541 reaction mixture Substances 0.000 description 144
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 124
• 239000000543 intermediate Substances 0.000 description 101
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 99
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 88
• 239000000203 mixture Substances 0.000 description 84
• 239000002904 solvent Substances 0.000 description 79
• 230000002829 reductive effect Effects 0.000 description 74
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
• 235000019439 ethyl acetate Nutrition 0.000 description 64
• 229910052757 nitrogen Inorganic materials 0.000 description 64
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
• 239000012043 crude product Substances 0.000 description 50
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 43
• 229910052938 sodium sulfate Inorganic materials 0.000 description 43
• 235000011152 sodium sulphate Nutrition 0.000 description 43
• 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 41
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 40
• 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 40
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 40
• 239000012044 organic layer Substances 0.000 description 40
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 36
• 238000006243 chemical reaction Methods 0.000 description 34
• 239000012267 brine Substances 0.000 description 31
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
• 238000005160 1H NMR spectroscopy Methods 0.000 description 29
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
• 239000003480 eluent Substances 0.000 description 28
• 125000001072 heteroaryl group Chemical group 0.000 description 28
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 26
• 238000004949 mass spectrometry Methods 0.000 description 25
• 239000000047 product Substances 0.000 description 25
• 125000000623 heterocyclic group Chemical group 0.000 description 23
• 101150111783 NTRK1 gene Proteins 0.000 description 22
• QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 22
• 125000004122 cyclic group Chemical group 0.000 description 22
• 238000004440 column chromatography Methods 0.000 description 21
• 239000000243 solution Substances 0.000 description 21
• 125000004429 atom Chemical group 0.000 description 20
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• 101150056950 Ntrk2 gene Proteins 0.000 description 18
• 239000003795 chemical substances by application Substances 0.000 description 18
• 125000004093 cyano group Chemical group *C#N 0.000 description 18
• 235000019253 formic acid Nutrition 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 239000000741 silica gel Substances 0.000 description 18
• 229910002027 silica gel Inorganic materials 0.000 description 18
• 125000001424 substituent group Chemical group 0.000 description 18
• 238000005481 NMR spectroscopy Methods 0.000 description 17
• 125000004076 pyridyl group Chemical group 0.000 description 17
• 125000003118 aryl group Chemical group 0.000 description 16
• 238000002953 preparative HPLC Methods 0.000 description 16
• 102000015336 Nerve Growth Factor Human genes 0.000 description 15
• 230000000694 effects Effects 0.000 description 15
• 229940053128 nerve growth factor Drugs 0.000 description 15
• 125000000335 thiazolyl group Chemical group 0.000 description 14
• 238000004809 thin layer chromatography Methods 0.000 description 14
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 13
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 13
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 13
• 238000009472 formulation Methods 0.000 description 13
• 125000001041 indolyl group Chemical group 0.000 description 13
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 12
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
• 125000001544 thienyl group Chemical group 0.000 description 12
• 239000002585 base Substances 0.000 description 11
• 239000010410 layer Substances 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 11
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
• 125000002619 bicyclic group Chemical group 0.000 description 10
• 229910052799 carbon Inorganic materials 0.000 description 10
• 125000005842 heteroatom Chemical group 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 238000011321 prophylaxis Methods 0.000 description 10
• 125000002098 pyridazinyl group Chemical group 0.000 description 10
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 10
• 101150035467 BDNF gene Proteins 0.000 description 9
• 101150117329 NTRK3 gene Proteins 0.000 description 9
• 239000005457 ice water Substances 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 9
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 8
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 8
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 8
• 210000004556 brain Anatomy 0.000 description 8
• 125000004432 carbon atom Chemical group C* 0.000 description 8
• 125000000753 cycloalkyl group Chemical group 0.000 description 8
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 8
• 230000000144 pharmacologic effect Effects 0.000 description 8
• 125000000714 pyrimidinyl group Chemical group 0.000 description 8
• 239000007787 solid Substances 0.000 description 8
• ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 7
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 7
• 238000004587 chromatography analysis Methods 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 102000013498 tau Proteins Human genes 0.000 description 7
• 108010026424 tau Proteins Proteins 0.000 description 7
• CGVLIAHKQBNAOM-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-phenoxyphenyl]-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound ClCC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O CGVLIAHKQBNAOM-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 6
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 6
• 201000007960 WAGR syndrome Diseases 0.000 description 6
• 239000000556 agonist Substances 0.000 description 6
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 6
• 239000001099 ammonium carbonate Substances 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 230000019771 cognition Effects 0.000 description 6
• 230000006806 disease prevention Effects 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 230000004410 intraocular pressure Effects 0.000 description 6
• 230000015654 memory Effects 0.000 description 6
• 210000002569 neuron Anatomy 0.000 description 6
• 239000012299 nitrogen atmosphere Substances 0.000 description 6
• 229910000104 sodium hydride Inorganic materials 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 5
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
• 208000010412 Glaucoma Diseases 0.000 description 5
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 5
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 5
• 108090000742 Neurotrophin 3 Proteins 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 108010005774 beta-Galactosidase Proteins 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000001713 cholinergic effect Effects 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 238000001914 filtration Methods 0.000 description 5
• 238000003818 flash chromatography Methods 0.000 description 5
• 239000007789 gas Substances 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 230000000971 hippocampal effect Effects 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• 206010069732 neurotrophic keratopathy Diseases 0.000 description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 description 5
• DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 125000003367 polycyclic group Chemical group 0.000 description 5
• 125000006239 protecting group Chemical group 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 238000010992 reflux Methods 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• 125000004306 triazinyl group Chemical group 0.000 description 5
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 5
• OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 description 4
• JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 4
• 108700028369 Alleles Proteins 0.000 description 4
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
• CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 4
• 102100026189 Beta-galactosidase Human genes 0.000 description 4
• 208000030814 Eating disease Diseases 0.000 description 4
• 208000019454 Feeding and Eating disease Diseases 0.000 description 4
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 102000035181 adaptor proteins Human genes 0.000 description 4
• 108091005764 adaptor proteins Proteins 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 229910021529 ammonia Inorganic materials 0.000 description 4
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
• 231100000895 deafness Toxicity 0.000 description 4
• 235000014632 disordered eating Nutrition 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 125000001786 isothiazolyl group Chemical group 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
• 125000001715 oxadiazolyl group Chemical group 0.000 description 4
• 125000002971 oxazolyl group Chemical group 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 4
• 125000003944 tolyl group Chemical group 0.000 description 4
• QLRUXCXWKIHWFP-UHFFFAOYSA-N 1-(3-hydroxy-4-phenoxyphenyl)-3-(3-methylphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound OC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O QLRUXCXWKIHWFP-UHFFFAOYSA-N 0.000 description 3
• AAOWBHHSJCRBRN-UHFFFAOYSA-N 1-(3-hydroxy-4-phenoxyphenyl)-3-(3-methylphenyl)urea Chemical compound OC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC(=CC=C1)C)=O AAOWBHHSJCRBRN-UHFFFAOYSA-N 0.000 description 3
• YWRZMBTZBSTEKG-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-phenoxyphenyl]-3-phenyl-1,3,5-triazinane-2,4,6-trione Chemical compound ClCC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=CC=C1)=O YWRZMBTZBSTEKG-UHFFFAOYSA-N 0.000 description 3
• UIZUXKLHWGHJPH-UHFFFAOYSA-N 2-(bromomethyl)-4-nitro-1-phenoxybenzene Chemical compound [O-][N+](=O)c1ccc(Oc2ccccc2)c(CBr)c1 UIZUXKLHWGHJPH-UHFFFAOYSA-N 0.000 description 3
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
• 239000005695 Ammonium acetate Substances 0.000 description 3
• 206010002653 Anosmia Diseases 0.000 description 3
• 201000001320 Atherosclerosis Diseases 0.000 description 3
• 208000020925 Bipolar disease Diseases 0.000 description 3
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
• 206010066131 Congenital central hypoventilation syndrome Diseases 0.000 description 3
• 208000001914 Fragile X syndrome Diseases 0.000 description 3
• 208000024412 Friedreich ataxia Diseases 0.000 description 3
• 208000011688 Generalised anxiety disease Diseases 0.000 description 3
• 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
• 206010050515 Hyposmia Diseases 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• 102100022340 SHC-transforming protein 1 Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 235000019257 ammonium acetate Nutrition 0.000 description 3
• 229940043376 ammonium acetate Drugs 0.000 description 3
• 239000000935 antidepressant agent Substances 0.000 description 3
• 229940005513 antidepressants Drugs 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 3
• 230000005587 bubbling Effects 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000000544 cholinesterase inhibitor Substances 0.000 description 3
• 230000006999 cognitive decline Effects 0.000 description 3
• 230000003920 cognitive function Effects 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 230000005176 gastrointestinal motility Effects 0.000 description 3
• 208000029364 generalized anxiety disease Diseases 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 235000019559 hyposmia Nutrition 0.000 description 3
• 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 208000037906 ischaemic injury Diseases 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000027928 long-term synaptic potentiation Effects 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000007659 motor function Effects 0.000 description 3
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 210000001178 neural stem cell Anatomy 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 208000008795 neuromyelitis optica Diseases 0.000 description 3
• 230000000324 neuroprotective effect Effects 0.000 description 3
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 3
• 208000001797 obstructive sleep apnea Diseases 0.000 description 3
• 210000002475 olfactory pathway Anatomy 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 208000028173 post-traumatic stress disease Diseases 0.000 description 3
• 230000002980 postoperative effect Effects 0.000 description 3
• NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 210000004129 prosencephalon Anatomy 0.000 description 3
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 3
• 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 201000002859 sleep apnea Diseases 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 125000001113 thiadiazolyl group Chemical group 0.000 description 3
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 3
• 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 3
• 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 3
• 102000015533 trkA Receptor Human genes 0.000 description 3
• 108010064884 trkA Receptor Proteins 0.000 description 3
• 102000015534 trkB Receptor Human genes 0.000 description 3
• 108010064880 trkB Receptor Proteins 0.000 description 3
• KDCLNGXDWFXVBW-UHFFFAOYSA-N (1-ethylpyrazol-4-yl)-(5-nitro-2-phenoxyphenyl)methanol Chemical compound C(C)N1N=CC(=C1)C(O)C1=C(C=CC(=C1)[N+](=O)[O-])OC1=CC=CC=C1 KDCLNGXDWFXVBW-UHFFFAOYSA-N 0.000 description 2
• VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 description 2
• SUNOCBMAOHKDTF-UHFFFAOYSA-N (5-amino-2-phenoxyphenyl)methanol Chemical compound NC=1C=CC(=C(C=1)CO)OC1=CC=CC=C1 SUNOCBMAOHKDTF-UHFFFAOYSA-N 0.000 description 2
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• MMMQRUASGOVQEY-UHFFFAOYSA-N 1-(2-fluoro-5-nitrophenyl)-4-methylimidazole Chemical compound FC1=C(C=C(C=C1)[N+](=O)[O-])N1C=NC(=C1)C MMMQRUASGOVQEY-UHFFFAOYSA-N 0.000 description 2
• CPGFZRJUWNXFTJ-UHFFFAOYSA-N 1-(3-methylphenyl)-3-(4-phenoxy-3-phenylmethoxyphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C(C1=CC=CC=C1)OC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC(=CC=C1)C)=O CPGFZRJUWNXFTJ-UHFFFAOYSA-N 0.000 description 2
• UJIMGEBRYZSQCO-UHFFFAOYSA-N 1-(3-methylphenyl)-3-(4-phenoxy-3-phenylmethoxyphenyl)urea Chemical compound C(C1=CC=CC=C1)OC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC(=CC=C1)C)=O UJIMGEBRYZSQCO-UHFFFAOYSA-N 0.000 description 2
• OYXWZWIIMVNAKH-UHFFFAOYSA-N 1-[(5-nitro-2-phenoxyphenyl)methyl]imidazole Chemical compound C=1N(C=CN=1)CC1=C(OC2=CC=CC=C2)C=CC(N(=O)=O)=C1 OYXWZWIIMVNAKH-UHFFFAOYSA-N 0.000 description 2
• OCFDXJCUZALXLP-UHFFFAOYSA-N 1-[(5-nitro-2-phenoxyphenyl)methyl]pyrazole Chemical compound C=1N(N=CC=1)CC1=C(OC2=CC=CC=C2)C=CC(N(=O)=O)=C1 OCFDXJCUZALXLP-UHFFFAOYSA-N 0.000 description 2
• UOUFSUYKLJSNNM-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-phenoxyphenyl]-3-(3-methylphenyl)urea Chemical compound ClCC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC(=CC=C1)C)=O UOUFSUYKLJSNNM-UHFFFAOYSA-N 0.000 description 2
• DZKCFILRQOFIKJ-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-phenoxyphenyl]-3-(4-methoxyphenyl)-1,3,5-triazinane-2,4,6-trione Chemical compound ClCC=1C=C(C=CC=1OC1=CC=CC=C1)N1C(N(C(NC1=O)=O)C1=CC=C(C=C1)OC)=O DZKCFILRQOFIKJ-UHFFFAOYSA-N 0.000 description 2
• NCSRNXGTRPXOOO-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-phenoxyphenyl]-3-phenylurea Chemical compound ClCC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC=CC=C1)=O NCSRNXGTRPXOOO-UHFFFAOYSA-N 0.000 description 2
• VOPZVSJFPVTNDC-UHFFFAOYSA-N 1-[3-(hydroxymethyl)-4-phenoxyphenyl]-3-(3-methylphenyl)urea Chemical compound OCC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC(=CC=C1)C)=O VOPZVSJFPVTNDC-UHFFFAOYSA-N 0.000 description 2
• AREVMGPKZNEPOF-UHFFFAOYSA-N 1-[3-(hydroxymethyl)-4-phenoxyphenyl]-3-(4-methoxyphenyl)urea Chemical compound OCC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC=C(C=C1)OC)=O AREVMGPKZNEPOF-UHFFFAOYSA-N 0.000 description 2
• YBIJPZGDXNNBHO-UHFFFAOYSA-N 1-[3-(hydroxymethyl)-4-phenoxyphenyl]-3-phenylurea Chemical compound OCC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC=CC=C1)=O YBIJPZGDXNNBHO-UHFFFAOYSA-N 0.000 description 2
• VNSVQJIDTLOQJI-UHFFFAOYSA-N 1-[3-(imidazol-1-ylmethyl)-4-phenoxyphenyl]-3-phenylurea Chemical compound N1(C=NC=C1)CC=1C=C(C=CC=1OC1=CC=CC=C1)NC(=O)NC1=CC=CC=C1 VNSVQJIDTLOQJI-UHFFFAOYSA-N 0.000 description 2
• GJWWJCVYUWECEB-UHFFFAOYSA-N 1-[3-[(1-ethylpyrazol-4-yl)methyl]-4-phenoxyphenyl]-3-phenylurea Chemical compound C(C)N1N=CC(=C1)CC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC=CC=C1)=O GJWWJCVYUWECEB-UHFFFAOYSA-N 0.000 description 2
• BVWNFDDTRJYAQE-UHFFFAOYSA-N 1-[4-(4-ethylphenoxy)-3-(pyrazol-1-ylmethyl)phenyl]-3-methylurea Chemical compound C1=CN(N=C1)CC1=C(OC2=CC=C(CC)C=C2)C=CC(NC(=O)NC)=C1 BVWNFDDTRJYAQE-UHFFFAOYSA-N 0.000 description 2
• PQWDXKISMQMOSZ-UHFFFAOYSA-N 1-[4-(4-fluorophenoxy)-3-(imidazol-1-ylmethyl)phenyl]-3-(3-methylphenyl)urea Chemical compound FC1=CC=C(OC2=C(C=C(C=C2)NC(NC2=CC(=CC=C2)C)=O)CN2C=NC=C2)C=C1 PQWDXKISMQMOSZ-UHFFFAOYSA-N 0.000 description 2
• OPFNJWQBZWXRBW-UHFFFAOYSA-N 1-[4-phenoxy-3-(pyrazol-1-ylmethyl)phenyl]-3-phenylurea Chemical compound C=1N(N=CC=1)CC1=C(OC2=CC=CC=C2)C=CC(NC(=O)NC2=CC=CC=C2)=C1 OPFNJWQBZWXRBW-UHFFFAOYSA-N 0.000 description 2
• YXKXVHRVQHXSON-UHFFFAOYSA-N 1-[5-[3-(4-methylimidazol-1-yl)-4-phenoxyphenyl]-1-(3-methylphenyl)-4-methylsulfanyl-6-oxo-1,3,5-triazin-2-ylidene]-3-(3-methylphenyl)urea Chemical compound CC=1N=CN(C=1)C=1C=C(C=CC=1OC1=CC=CC=C1)N1C(=NC(N(C1=O)C1=CC(=CC=C1)C)=NC(NC1=CC(=CC=C1)C)=O)SC YXKXVHRVQHXSON-UHFFFAOYSA-N 0.000 description 2
• RCXHONXQCRKMBJ-UHFFFAOYSA-N 1-[[2-(4-ethylphenoxy)-5-nitrophenyl]methyl]pyrazole Chemical compound C1=CN(N=C1)CC1=C(OC2=CC=C(C=C2)CC)C=CC(N(=O)=O)=C1 RCXHONXQCRKMBJ-UHFFFAOYSA-N 0.000 description 2
• HPFHSTIWDMQQFE-UHFFFAOYSA-N 1-[[2-(4-fluorophenoxy)-5-nitrophenyl]methyl]imidazole Chemical compound FC1=CC=C(OC2=C(C=C(C=C2)[N+](=O)[O-])CN2C=NC=C2)C=C1 HPFHSTIWDMQQFE-UHFFFAOYSA-N 0.000 description 2
• IBTZSBWOOFITOB-UHFFFAOYSA-N 1-ethyl-4-[(5-nitro-2-phenoxyphenyl)methyl]pyrazole Chemical compound C(C)N1N=CC(=C1)CC1=C(C=CC(=C1)[N+](=O)[O-])OC1=CC=CC=C1 IBTZSBWOOFITOB-UHFFFAOYSA-N 0.000 description 2
• CPPGZWWUPFWALU-UHFFFAOYSA-N 1-isocyanato-3-methylbenzene Chemical compound CC1=CC=CC(N=C=O)=C1 CPPGZWWUPFWALU-UHFFFAOYSA-N 0.000 description 2
• OBSBJXBUSFXWST-UHFFFAOYSA-N 1-methyl-3-[4-phenyl-3-(pyrazol-1-ylmethyl)phenyl]urea Chemical compound N1(C=CC=N1)CC1=C(C2=CC=CC=C2)C=CC(NC(=O)NC)=C1 OBSBJXBUSFXWST-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• FHQJATCRBWUVMR-UHFFFAOYSA-N 3-(4-methylimidazol-1-yl)-4-phenoxyaniline Chemical compound CC=1N=CN(C=1)C=1C=C(N)C=CC=1OC1=CC=CC=C1 FHQJATCRBWUVMR-UHFFFAOYSA-N 0.000 description 2
• IGABOHNRILHWCV-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)-4-phenoxyaniline Chemical compound C=1N(C=CN=1)CC1=C(OC2=CC=CC=C2)C=CC(N)=C1 IGABOHNRILHWCV-UHFFFAOYSA-N 0.000 description 2
• OICDWCBJAVNUEV-UHFFFAOYSA-N 4-(4-ethylphenoxy)-3-(pyrazol-1-ylmethyl)aniline Chemical compound C=1N(N=CC=1)CC1=C(OC2=CC=C(C=C2)CC)C=CC(N)=C1 OICDWCBJAVNUEV-UHFFFAOYSA-N 0.000 description 2
• FKUBGKGKYBBNQX-UHFFFAOYSA-N 4-(4-fluorophenoxy)-3-(imidazol-1-ylmethyl)aniline Chemical compound FC1=CC=C(OC2=C(C=C(N)C=C2)CN2C=NC=C2)C=C1 FKUBGKGKYBBNQX-UHFFFAOYSA-N 0.000 description 2
• RYXJXPHWRBWEEB-UHFFFAOYSA-N 4-fluoro-1h-pyrazole Chemical compound FC=1C=NNC=1 RYXJXPHWRBWEEB-UHFFFAOYSA-N 0.000 description 2
• DGISYKUBKBBTKI-UHFFFAOYSA-N 4-methyl-1-(5-nitro-2-phenoxyphenyl)imidazole Chemical compound CC=1N=CN(C=1)C1=C(C=CC(=C1)[N+](=O)[O-])OC1=CC=CC=C1 DGISYKUBKBBTKI-UHFFFAOYSA-N 0.000 description 2
• XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
• RHSDEYUSKBUVRA-UHFFFAOYSA-N 4-phenoxy-3-(pyrazol-1-ylmethyl)aniline Chemical compound N1(C=CC=N1)CC1=C(OC2=CC=CC=C2)C=CC(N)=C1 RHSDEYUSKBUVRA-UHFFFAOYSA-N 0.000 description 2
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
• COCYGNDCWFKTMF-UHFFFAOYSA-N 7,8-dihydroxyflavone Chemical compound OC=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 COCYGNDCWFKTMF-UHFFFAOYSA-N 0.000 description 2
• 102000012440 Acetylcholinesterase Human genes 0.000 description 2
• 108010022752 Acetylcholinesterase Proteins 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• 208000000103 Anorexia Nervosa Diseases 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 102100026376 Artemin Human genes 0.000 description 2
• 101710205806 Artemin Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 2
• 101710101214 BDNF/NT-3 growth factors receptor Proteins 0.000 description 2
• 206010006550 Bulimia nervosa Diseases 0.000 description 2
• AICFSEFWOGSBES-UHFFFAOYSA-N C(C)N1N=CC(=C1)CC=1C=C(N)C=CC=1OC1=CC=CC=C1 Chemical compound C(C)N1N=CC(=C1)CC=1C=C(N)C=CC=1OC1=CC=CC=C1 AICFSEFWOGSBES-UHFFFAOYSA-N 0.000 description 2
• 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
• 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
• 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000825399 Homo sapiens SHC-transforming protein 1 Proteins 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 102000014429 Insulin-like growth factor Human genes 0.000 description 2
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
• 208000001089 Multiple system atrophy Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• UHVRLBICVMSNAH-UHFFFAOYSA-N N-(2-fluoro-5-nitrophenyl)-N-(2-oxopropyl)formamide Chemical compound FC1=C(C=C(C=C1)[N+](=O)[O-])N(C=O)CC(C)=O UHVRLBICVMSNAH-UHFFFAOYSA-N 0.000 description 2
• FECVQPJDRUMVIX-UHFFFAOYSA-N NC(C=C1)=CC(CN2N=CN=C2)=C1OC1=CC=CC=C1 Chemical compound NC(C=C1)=CC(CN2N=CN=C2)=C1OC1=CC=CC=C1 FECVQPJDRUMVIX-UHFFFAOYSA-N 0.000 description 2
• 102100029166 NT-3 growth factor receptor Human genes 0.000 description 2
• 101710145851 NT-3 growth factor receptor Proteins 0.000 description 2
• 102000004230 Neurotrophin 3 Human genes 0.000 description 2
• 108090000099 Neurotrophin-4 Proteins 0.000 description 2
• 102100021584 Neurturin Human genes 0.000 description 2
• 108010015406 Neurturin Proteins 0.000 description 2
• TZNRLMJSTIWTNK-UHFFFAOYSA-N O=C(NC1=CC=CC=C1)NC(C=C1)=CC(CN2N=CN=C2)=C1OC1=CC=CC=C1 Chemical compound O=C(NC1=CC=CC=C1)NC(C=C1)=CC(CN2N=CN=C2)=C1OC1=CC=CC=C1 TZNRLMJSTIWTNK-UHFFFAOYSA-N 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 102100036660 Persephin Human genes 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
• 201000004810 Vascular dementia Diseases 0.000 description 2
• FGDJFMCKKOJOQE-UHFFFAOYSA-N [O-][N+](C(C=C1)=CC(CN2N=CN=C2)=C1OC1=CC=CC=C1)=O Chemical compound [O-][N+](C(C=C1)=CC(CN2N=CN=C2)=C1OC1=CC=CC=C1)=O FGDJFMCKKOJOQE-UHFFFAOYSA-N 0.000 description 2
• 229940022698 acetylcholinesterase Drugs 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 229960005305 adenosine Drugs 0.000 description 2
• 102000003802 alpha-Synuclein Human genes 0.000 description 2
• 108090000185 alpha-Synuclein Proteins 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
• 230000007131 anti Alzheimer effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 229940125688 antiparkinson agent Drugs 0.000 description 2
• 239000003693 atypical antipsychotic agent Substances 0.000 description 2
• 229940127236 atypical antipsychotics Drugs 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• 239000002439 beta secretase inhibitor Substances 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 210000002932 cholinergic neuron Anatomy 0.000 description 2
• 239000002475 cognitive enhancer Substances 0.000 description 2
• 230000007370 cognitive improvement Effects 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 150000001923 cyclic compounds Chemical class 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000006735 deficit Effects 0.000 description 2
• 238000010511 deprotection reaction Methods 0.000 description 2
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 238000003174 enzyme fragment complementation Methods 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 238000001640 fractional crystallisation Methods 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 208000008675 hereditary spastic paraplegia Diseases 0.000 description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
• 230000008991 intestinal motility Effects 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 201000010901 lateral sclerosis Diseases 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• GNXCIXIOUAHPHZ-UHFFFAOYSA-N methyl 2-phenoxy-5-(phenylcarbamoylamino)benzoate Chemical compound C=1C=C(OC=2C=CC=CC=2)C(C(=O)OC)=CC=1NC(=O)NC1=CC=CC=C1 GNXCIXIOUAHPHZ-UHFFFAOYSA-N 0.000 description 2
• MOPOSIOGNAMBRR-UHFFFAOYSA-N methyl 5-[(3-methylphenyl)carbamoylamino]-2-phenoxybenzoate Chemical compound CC=1C=C(C=CC=1)NC(=O)NC=1C=CC(=C(C(=O)OC)C=1)OC1=CC=CC=C1 MOPOSIOGNAMBRR-UHFFFAOYSA-N 0.000 description 2
• MHAZEXGQGPSXRT-UHFFFAOYSA-N methyl 5-amino-2-phenoxybenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1OC1=CC=CC=C1 MHAZEXGQGPSXRT-UHFFFAOYSA-N 0.000 description 2
• SYKHXGRVHCRBFT-UHFFFAOYSA-N methyl N-cyano-N'-[3-(4-methylimidazol-1-yl)-4-phenoxyphenyl]carbamimidothioate Chemical compound C(#N)NC(=NC1=CC(=C(C=C1)OC1=CC=CC=C1)N1C=NC(=C1)C)SC SYKHXGRVHCRBFT-UHFFFAOYSA-N 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 230000000897 modulatory effect Effects 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• YQKWGXFWPKUHBW-UHFFFAOYSA-N n-(2-fluoro-5-nitrophenyl)formamide Chemical compound [O-][N+](=O)C1=CC=C(F)C(NC=O)=C1 YQKWGXFWPKUHBW-UHFFFAOYSA-N 0.000 description 2
• GRRYSIXDUIAUGY-UHFFFAOYSA-N n-methylcarbamoyl chloride Chemical compound CNC(Cl)=O GRRYSIXDUIAUGY-UHFFFAOYSA-N 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 230000002981 neuropathic effect Effects 0.000 description 2
• 230000004112 neuroprotection Effects 0.000 description 2
• 230000001928 neurorestorative effect Effects 0.000 description 2
• 229940032018 neurotrophin 3 Drugs 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 125000003566 oxetanyl group Chemical group 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 108010070453 persephin Proteins 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 201000002241 progressive bulbar palsy Diseases 0.000 description 2
• 201000008752 progressive muscular atrophy Diseases 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 239000003379 purinergic P1 receptor agonist Substances 0.000 description 2
• 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 description 2
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 2
• 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 2
• 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 2
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000007470 synaptic degeneration Effects 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 230000003956 synaptic plasticity Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 230000017423 tissue regeneration Effects 0.000 description 2
• 229960000898 toltrazuril Drugs 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229940124648 γ-Secretase Modulator Drugs 0.000 description 2
• MIAKOEWBCMPCQR-YBXAARCKSA-N (2s,3r,4s,5r,6r)-2-(4-aminophenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound C1=CC(N)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MIAKOEWBCMPCQR-YBXAARCKSA-N 0.000 description 1
• FTJULKDBHGTYLM-UHFFFAOYSA-N (5-nitro-2-phenoxyphenyl)methanol Chemical compound OCC1=CC([N+]([O-])=O)=CC=C1OC1=CC=CC=C1 FTJULKDBHGTYLM-UHFFFAOYSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical class OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
• JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
• FLOJNXXFMHCMMR-UHFFFAOYSA-N 1,3-dithiolanyl Chemical group [CH]1SCCS1 FLOJNXXFMHCMMR-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• QNZBZXHTGRIRSV-UHFFFAOYSA-N 1-[(5-nitro-2-phenylphenyl)methyl]pyrazole Chemical compound N1(C=CC=N1)CC1=C(C2=CC=CC=C2)C=CC(N(=O)=O)=C1 QNZBZXHTGRIRSV-UHFFFAOYSA-N 0.000 description 1
• LVSZRYXZXSERPK-UHFFFAOYSA-N 1-[3-(chloromethyl)-4-phenoxyphenyl]-3-(4-methoxyphenyl)urea Chemical compound ClCC=1C=C(C=CC=1OC1=CC=CC=C1)NC(NC1=CC=C(C=C1)OC)=O LVSZRYXZXSERPK-UHFFFAOYSA-N 0.000 description 1
• WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical class CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
• 102100026205 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Human genes 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• HWLIOOSQBXQNRG-UHFFFAOYSA-N 2-(bromomethyl)-1-(4-ethylphenoxy)-4-nitrobenzene Chemical compound CCc1ccc(Oc2ccc(cc2CBr)[N+]([O-])=O)cc1 HWLIOOSQBXQNRG-UHFFFAOYSA-N 0.000 description 1
• UKISYSJPGXZVRO-UHFFFAOYSA-N 2-(bromomethyl)-1-(4-fluorophenoxy)-4-nitrobenzene Chemical compound [O-][N+](=O)c1ccc(Oc2ccc(F)cc2)c(CBr)c1 UKISYSJPGXZVRO-UHFFFAOYSA-N 0.000 description 1
• NJEKNMVWNDFCSH-UHFFFAOYSA-N 2-(bromomethyl)-1h-imidazole;hydrobromide Chemical compound Br.BrCC1=NC=CN1 NJEKNMVWNDFCSH-UHFFFAOYSA-N 0.000 description 1
• SEJGUDPANOBNKI-UHFFFAOYSA-N 2-(bromomethyl)-4-nitro-1-phenylbenzene Chemical group BrCC1=C(C=CC(=C1)[N+](=O)[O-])C1=CC=CC=C1 SEJGUDPANOBNKI-UHFFFAOYSA-N 0.000 description 1
• KQCCIFJFIWIAPH-UHFFFAOYSA-N 2-[5-[3-(3-methylphenyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]-2-phenoxyphenoxy]acetic acid Chemical compound CC=1C=C(C=CC=1)N1C(N(C(NC1=O)=O)C=1C=CC(=C(OCC(=O)O)C=1)OC1=CC=CC=C1)=O KQCCIFJFIWIAPH-UHFFFAOYSA-N 0.000 description 1
• MNURPFVONZPVLA-UHFFFAOYSA-N 2-chlorobenzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1Cl MNURPFVONZPVLA-UHFFFAOYSA-N 0.000 description 1
• KJVBJICWGQIMOZ-UHFFFAOYSA-N 2-fluoro-5-nitroaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1F KJVBJICWGQIMOZ-UHFFFAOYSA-N 0.000 description 1
• AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
• RXELBMYKBFKHSM-UHFFFAOYSA-N 2-phenyl-1,3,5-triazine Chemical class C1=CC=CC=C1C1=NC=NC=N1 RXELBMYKBFKHSM-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• 238000011825 3xTg-AD mouse Methods 0.000 description 1
• IPMSARLBJARXSC-UHFFFAOYSA-N 4-bromo-1-ethylpyrazole Chemical compound CCN1C=C(Br)C=N1 IPMSARLBJARXSC-UHFFFAOYSA-N 0.000 description 1
• IHNXHUNMFYXQCG-UHFFFAOYSA-N 4-ethyl-1h-pyrazole Chemical compound CCC=1C=NNC=1 IHNXHUNMFYXQCG-UHFFFAOYSA-N 0.000 description 1
• 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
• HCGYTFXTHWTYFK-UHFFFAOYSA-N 5-(chloromethyl)-1h-imidazole Chemical compound ClCC1=CN=CN1 HCGYTFXTHWTYFK-UHFFFAOYSA-N 0.000 description 1
• TTZNPYSLZLYZLZ-UHFFFAOYSA-N 5-amino-2-phenoxyphenol Chemical compound OC1=CC(N)=CC=C1OC1=CC=CC=C1 TTZNPYSLZLYZLZ-UHFFFAOYSA-N 0.000 description 1
• HWUPTWDARIVICI-UHFFFAOYSA-N 5-fluoro-1h-imidazole Chemical compound FC1=CN=CN1 HWUPTWDARIVICI-UHFFFAOYSA-N 0.000 description 1
• UILWHYLTBYVYOU-UHFFFAOYSA-N 5-nitro-2-phenoxybenzaldehyde Chemical compound O=CC1=CC([N+](=O)[O-])=CC=C1OC1=CC=CC=C1 UILWHYLTBYVYOU-UHFFFAOYSA-N 0.000 description 1
• WWGFXSLWIRYIBP-UHFFFAOYSA-N 7,8-dihydroxy-4H-chromen-4-one Natural products O1C=CC(=O)C=2C1=C(O)C(O)=CC=2 WWGFXSLWIRYIBP-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 102400000069 Activation peptide Human genes 0.000 description 1
• 101800001401 Activation peptide Proteins 0.000 description 1
• 241001209435 Actus Species 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 206010006100 Bradykinesia Diseases 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000009846 Central Nervous System Protozoal Infections Diseases 0.000 description 1
• 208000007102 Chronic Brain Damage Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 108010055334 EphB2 Receptor Proteins 0.000 description 1
• 101710114534 Ephrin type-B receptor 2 Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 108010001589 Glial Cell Line-Derived Neurotrophic Factors Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 101000691599 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000006083 Hypokinesia Diseases 0.000 description 1
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 102000003683 Neurotrophin-4 Human genes 0.000 description 1
• 102100033857 Neurotrophin-4 Human genes 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 206010030043 Ocular hypertension Diseases 0.000 description 1
• 208000012898 Olfaction disease Diseases 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108010056751 Phospholipase C gamma Proteins 0.000 description 1
• 102000004422 Phospholipase C gamma Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
• 208000005107 Premature Birth Diseases 0.000 description 1
• 206010036590 Premature baby Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 102100032889 Sortilin Human genes 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical class OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
• 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• VOUDTVRGPAGHGA-SQIPALKSSA-N [(1r,4br,5r,6ar,10ar,10br,12ar)-1-(furan-3-yl)-4b,7,7,10a,12a-pentamethyl-3,8-dioxo-5,6,6a,10b,11,12-hexahydro-1h-naphtho[2,1-f]isochromen-5-yl] acetate Chemical compound C=1([C@H]2[C@]3(C)CC[C@@H]4[C@@]5(C)C=CC(=O)C(C)(C)[C@@H]5C[C@H]([C@]4(C3=CC(=O)O2)C)OC(=O)C)C=COC=1 VOUDTVRGPAGHGA-SQIPALKSSA-N 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
• 230000007792 alzheimer disease pathology Effects 0.000 description 1
• KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
• 229960000836 amitriptyline Drugs 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 239000000883 anti-obesity agent Substances 0.000 description 1
• 230000000842 anti-protozoal effect Effects 0.000 description 1
• 230000000320 anti-stroke effect Effects 0.000 description 1
• 229940125710 antiobesity agent Drugs 0.000 description 1
• 239000003904 antiprotozoal agent Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
• 125000003725 azepanyl group Chemical group 0.000 description 1
• 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• IULFXBLVJIPESI-UHFFFAOYSA-N bis(methylsulfanyl)methylidenecyanamide Chemical compound CSC(SC)=NC#N IULFXBLVJIPESI-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 150000001649 bromium compounds Chemical class 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 125000002837 carbocyclic group Chemical group 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000005961 cardioprotection Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 239000003467 chloride channel stimulating agent Substances 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 229940114081 cinnamate Drugs 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000000000 cycloalkoxy group Chemical group 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000020335 dealkylation Effects 0.000 description 1
• 238000006900 dealkylation reaction Methods 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 230000013872 defecation Effects 0.000 description 1
• 238000006356 dehydrogenation reaction Methods 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000007267 depressive like behavior Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 125000005959 diazepanyl group Chemical group 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
• 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
• 238000006345 epimerization reaction Methods 0.000 description 1
• 230000001073 episodic memory Effects 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• 238000006266 etherification reaction Methods 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• KIZYGRMVMJOKDR-UHFFFAOYSA-N ethyl 2-[5-[(3-methylphenyl)carbamoylamino]-2-phenoxyphenoxy]acetate Chemical compound CC=1C=C(C=CC=1)NC(=O)NC=1C=CC(=C(OCC(=O)OCC)C=1)OC1=CC=CC=C1 KIZYGRMVMJOKDR-UHFFFAOYSA-N 0.000 description 1
• DFZFBFFRVPCOCI-UHFFFAOYSA-N ethyl 2-[5-[3-(3-methylphenyl)-2,4,6-trioxo-1,3,5-triazinan-1-yl]-2-phenoxyphenoxy]acetate Chemical compound CC=1C=C(C=CC=1)N1C(N(C(NC1=O)=O)C=1C=CC(=C(OCC(=O)OCC)C=1)OC1=CC=CC=C1)=O DFZFBFFRVPCOCI-UHFFFAOYSA-N 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000015756 familial Alzheimer disease Diseases 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• NFVXKLYWFCNBCO-RRZNCOCZSA-N gambogic amide Chemical compound C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(\C)C(N)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O NFVXKLYWFCNBCO-RRZNCOCZSA-N 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 230000026030 halogenation Effects 0.000 description 1
• 238000005658 halogenation reaction Methods 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
• 230000008801 hippocampal function Effects 0.000 description 1
• 230000009808 hippocampal neurogenesis Effects 0.000 description 1
• 210000004295 hippocampal neuron Anatomy 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000008141 laxative Substances 0.000 description 1
• 229940125722 laxative agent Drugs 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
• 229960001571 loperamide Drugs 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 150000004701 malic acid derivatives Chemical class 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 239000003695 memory enhancer Substances 0.000 description 1
• 230000006883 memory enhancing effect Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 125000005341 metaphosphate group Chemical group 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 150000002742 methionines Chemical class 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 239000000693 micelle Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 208000001022 morbid obesity Diseases 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 230000035771 neuroregeneration Effects 0.000 description 1
• 239000003900 neurotrophic factor Substances 0.000 description 1
• 229940097998 neurotrophin 4 Drugs 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 238000006396 nitration reaction Methods 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 150000003891 oxalate salts Chemical class 0.000 description 1
• 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• 229950009215 phenylbutanoic acid Drugs 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 125000005498 phthalate group Chemical class 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 238000000053 physical method Methods 0.000 description 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
• 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
• UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 201000000196 pseudobulbar palsy Diseases 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 108091008600 receptor tyrosine phosphatases Proteins 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 239000013557 residual solvent Substances 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 102200143520 rs6265 Human genes 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 239000007962 solid dispersion Substances 0.000 description 1
• 239000012265 solid product Substances 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 150000003413 spiro compounds Chemical class 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
• 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
• 239000011593 sulfur Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 238000003419 tautomerization reaction Methods 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000002053 thietanyl group Chemical group 0.000 description 1
• 125000001730 thiiranyl group Chemical group 0.000 description 1
• 125000001166 thiolanyl group Chemical group 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 125000005455 trithianyl group Chemical group 0.000 description 1
• 238000001665 trituration Methods 0.000 description 1
• 102000047459 trkC Receptor Human genes 0.000 description 1
• 108010064892 trkC Receptor Proteins 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 238000002211 ultraviolet spectrum Methods 0.000 description 1
• 150000003680 valines Chemical class 0.000 description 1
• 239000003643 water by type Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1